Programs aimed at eliminating tuberculosis have improved throughout the United States, with most indicating reductions in disease incidence and higher rates of treatment completion.

In patients with latent tuberculosis, influenza-like reactions following treatment with isoniazid plus rifapentine or isoniazid alone were not associated with the presence of antibodies against isoniazid, rifapentine, and rifapentine metabolite.

The occurrence of adrenal insufficiency was relatively common in patients infected with HIV or TB and predicted by nonspecific clinical features, including weight loss, myalgia, arthralgia, and abdominal pain.

Virologic suppression can be maintained among patients with HIV infection receiving integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) in combination with short-course rifapentine-based regimens for latent tuberculosis (TB) management, according to study results published in Clinical Infectious Diseases.

Exposure to isoniazid prevention therapy during the first trimester of pregnancy is associated with increased risk for fetal demise, according to study results published in Clinical Infectious Diseases.

There was a low risk for post-treatment recurrence among patients who received treatment for multidrug- or rifampicin-resistant tuberculosis infection.

There was a significant gap in TB diagnostic care both before and during the COVID-19 pandemic among hospitalized patients with advanced HIV infection.

Weight-based dosing of bedaquiline for multidrug/rifampicin-resistant (MDR/RR) tuberculosis (TB) infection was safe and effective among children with and without HIV coinfection, according to findings published in Clinical Infectious Diseases.

Results of a study called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant tuberculosis (TB). These findings were published in the American Journal of Respiratory and Critical Care Medicine.

Results of a phase 3 randomized trial found that daily treatment with high-dose rifapentine for tuberculosis (TB) infection decreased efavirenz clearance and achieved therapeutic targets among patients coinfected with HIV receiving efavirenz-based antiretroviral therapy (ART). These findings were published in Clinical Infectious Diseases.